Editorial on: Pagonabarraga J, Martinez-Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug-naïve Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432

2015 ◽  
Vol 31 (1) ◽  
pp. 9-10 ◽  
Author(s):  
Joseph H. Friedman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorders ◽  
Drug Naïve ◽  
Premotor Phase

Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase

2015 ◽  
Vol 31 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Javier Pagonabarraga ◽  
Saul Martinez-Horta ◽  
Ramón Fernández de Bobadilla ◽  
Jesús Pérez ◽  
Roser Ribosa-Nogué ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Naïve ◽  
Premotor Phase

Analysis of Functional and Cognitive Impairment in Institutionalized Individuals with Movement Disorders

2019 ◽  
Vol 19 (7) ◽  
pp. 1022-1031 ◽  
Author(s):  
Paula D. Cebrián ◽  
Omar Cauli
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Activities Of Daily Living ◽  
Cognitive Performance ◽  
Functional Impairment ◽  
Movement Disorders ◽  
Neurological Disorders ◽  
Daily Living ◽  
Severe Cognitive Impairment

Background: Many neurological disorders lead to institutionalization and can be accompanied in their advanced stages by functional impairment, and progressive loss of mobility, and cognitive alterations. Objective: We analyzed the relationship between functional impairment and cognitive performance and its related subdomains in individuals with Parkinson’s disease, Alzheimer’s disease accompanied by motor dysfunction, and with other neurological disorders characterized by both motor and cognitive problems. Methods: All participants lived in nursing homes (Valencia, Spain) and underwent cognitive evaluation with the Mini-Mental State Examination; functional assessment of independence in activities of daily living using the Barthel score and Katz index; and assessment of mobility with the elderly mobility scale. Results: The mean age of the subjects was 82.8 ± 0.6 years, 47% of the sample included individuals with Parkinson’s disease, and 48 % of the sample presented severe cognitive impairment. Direct significant relationships were found between the level of cognitive impairment and functional capacity (p < 0.01) and mobility (p < 0.05). Among the different domains, memory impairment was not associated with altered activities of daily living or mobility. The functional impairment and the risk of severe cognitive impairment were significantly (p<0.05) higher in female compared to male patients. Among comorbidities, overweight/obesity and diabetes were significantly (p < 0.05) associated with poor cognitive performance in those individuals with mild/moderate cognitive impairment. Conclusion: In institutionalized individuals with movement disorders there is an association between functional and cognitive impairment. Reduction of over-weight and proper control of diabetes may represent novel targets for improving cognitive function at such early stages.

scholarly journals Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson’s Disease?

2021 ◽  
pp. 1-6
Author(s):  
Matt Landers ◽  
Suchi Saria ◽  
Alberto J. Espay
Keyword(s):  
Artificial Intelligence ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Precision Medicine ◽  
Movement Disorders ◽  
Living Environment ◽  
Patient Status ◽  
Patient Symptom ◽  
Molecular Therapies ◽  
Improve Patient

The use of artificial intelligence (AI) to help diagnose and manage disease is of increasing interest to researchers and clinicians. Volumes of health data are generated from smartphones and ubiquitous inexpensive sensors. By using these data, AI can offer otherwise unobtainable insights about disease burden and patient status in a free-living environment. Moreover, from clinical datasets AI can improve patient symptom monitoring and global epidemiologic efforts. While these applications are exciting, it is necessary to examine both the utility and limitations of these novel analytic methods. The most promising uses of AI remain aspirational. For example, defining the molecular subtypes of Parkinson’s disease will be assisted by future applications of AI to relevant datasets. This will allow clinicians to match patients to molecular therapies and will thus help launch precision medicine. Until AI proves its potential in pushing the frontier of precision medicine, its utility will primarily remain in individualized monitoring, complementing but not replacing movement disorders specialists.

Parkinson's disease and movement disorders

2001 ◽  
Vol 49 (6) ◽  
pp. 821-821
Author(s):  
Ronald F. Pfeiffer
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorders

Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease

2015 ◽  
Vol 230 (7) ◽  
pp. 1614-1629 ◽  
Author(s):  
Hany E.S. Marei ◽  
Samah Lashen ◽  
Amany Farag ◽  
Asmaa Althani ◽  
Nahla Afifi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Olfactory Bulb ◽  
Neural Stem Cells ◽  
Rat Model ◽  
Movement Disorders
Sign in / Sign up

Export Citation Format

Share Document